menu

TAG: CERES NANO

Ceres Nanosciences, University of Virginia, and George Mason University receive $600,000 award from the Virginia Catalyst to develop a Nanotrap® liquid biopsy collection device for cancer diagnostics

MANASSAS, Va. — June 4, 2019 — Ceres Nanosciences, Inc. (Ceres), University of Virginia (UVA), and George Mason University (Mason) today announced the receipt of a $600,000 award from the Virginia Catalyst for the development of a Nanotrap® liquid biopsy collection device. This award will be matched by $1.2 million in product development funding by Ceres Nanosciences. Cancer is the second leading cause of death world-wide and the global cancer burden is expected to grow to 23.6 million new cancer cases by 2030. Tissue biopsies are the current gold standard for detecting and obtaining information about cancer. By collecting cells from tumors, doctors can...

READ MORE
Ceres Nanosciences’ Point-of-Care Nanotrap® Lyme Antigen Test System Granted Breakthrough Device Designation by U.S. Food and Drug Administration.

Manassas, VA – July 12, 2018 – Ceres Nanosciences (Ceres) announced today that is has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its new point-of-care Nanotrap® Lyme Antigen Test System. Under the Breakthrough Device program, formerly the Expedited Access Pathways program, the FDA works with a test developer to reduce the time and cost from development to approval. The Ceres’ Nanotrap® Lyme Antigen Test System is a powerful diagnostic test that is intended to be available in point-of-care settings, like a physician’s office or a walk-in clinic. Requiring only a patient’s urine sample, it will...

READ MORE
Ceres Nanosciences reaches product development milestone for point-of-care Lyme disease test and closes on an additional $5.5M of Series A funding

Manassas, VA – May 31, 2018 – Ceres Nanosciences (Ceres) is announcing today that it has reached a key product development milestone for its Nanotrap® Lyme Antigen Test System. The Nanotrap® Lyme Antigen Test System will proceed into manufacturing and analytical performance testing this year and is on track for clinical study and FDA submission in 2019. “The Nanotrap® Lyme Antigen Test System presents a unique and powerful approach to dealing with Lyme disease. It will address the critical need for an accurate, direct test for early detection of a devastating disease and it will be available right in the...

READ MORE
Ceres Nanosciences announces plans for significant growth in Prince William County, Virginia

Prince William County, VA – December 12, 2017 – Ceres Nanosciences (Ceres) is pleased to announce its recent expansion in Prince William County, Virginia. Following a successful fundraising round in 2017, Ceres has rapidly expanded both its staff and its facilities to accommodate the growing demand for the novel Nanotrap® particle platform across the life sciences industry. The Nanotrap® particle provides enhanced sample processing capabilities to new and existing diagnostic tests for some of the most challenging diseases and conditions, such as Lyme disease, respiratory diseases, emerging infectious diseases and cancer detection, as well as for improved health and wellness monitoring....

READ MORE
Tasso, Ceres Nanosciences, George Mason University, and the United States Army Medical Research Institute of Infectious Diseases receive $4.25M to develop a universal surveillance platform for infectious disease outbreaks.

MANASSAS, Va. — September 28, 2017 — Tasso, Inc. (Tasso), Ceres Nanosciences (Ceres), George Mason University (Mason), and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) today announced the commencement of a $11.7 million program, funded by the Defense Threat Reduction Agency (DTRA), to develop a reliable, safe, and simple universal surveillance platform for infectious disease outbreaks. During this multi-year program, which will be initiated with $4.25 million in funding from DTRA, Ceres will integrate its Nanotrap® particle technology, which can capture, concentrate, and preserve pathogens and other biomolecules, into Tasso’s HemoLink™ device for simple and painless collection...

READ MORE
Ceres Nanosciences and Innatoss Laboratories to Launch the Nanotrap® Lyme Antigen Test in the European Union

The Nanotrap® Lyme Antigen Test, a direct urine test for the presence of a Lyme bacteria protein, will be made available to patients throughout Europe. Ceres Nanosciences, Inc. (Ceres) and Innatoss Laboratories (Innatoss) announced today a partnership that will deliver the Nanotrap® Lyme Antigen Test out of Innatoss’ clinical testing laboratories in the Netherlands for patient benefit throughout the European Union. The Nanotrap® Lyme Antigen Test is the first highly-sensitive, urine-based test capable of directly detecting a Lyme protein antigen in a patient at any stage of infection. In 2015, Ceres launched the Nanotrap® Lyme Antigen Test for patients across...

READ MORE
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER